+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Oligonucleotide Synthesis Market by End-users and Geography - Forecast and Analysis 2019-2023 - Product Image

Oligonucleotide Synthesis Market by End-users and Geography - Forecast and Analysis 2019-2023

  • ID: 4846449
  • Report
  • September 2019
  • Region: Global
  • 150 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Agilent Technologies Inc.
  • Danaher Corp.
  • General Electric Co.
  • GenScript Biotech Corp.
  • Kaneka Corp.
  • Merck KGaA
  • MORE
Global Oligonucleotide Synthesis Market: About this market

The oligonucleotide synthesis market analysis considers sales from pharmaceutical and biotechnology companies, research and academic institutes, diagnostic laboratories, and hospital end-users. Our analysis also considers the sales of oligonucleotide synthesis in Asia, Europe, North America, and ROW. In 2018, the pharmaceutical and biotechnology companies segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increase in research on the development of oligonucleotide therapeutics will play a significant role in the pharmaceutical and biotechnology companies segment to maintain its market position. Also, our global oligonucleotide synthesis market report looks at factors such as the increasing research activities in the pharmaceutical and biotechnology sectors, increasing use of oligonucleotides as therapeutic and diagnostic tools, and emergence of technological innovations in oligonucleotide synthesis. However, regulatory issues associated with oligonucleotide therapeutics, diversity in oligonucleotide molecules, and challenges in effective oligonucleotide delivery may hamper the growth of the oligonucleotide synthesis industry over the forecast period.

Global Oligonucleotide Synthesis Market: Overview

Increasing research activities in the pharmaceutical and biotechnology sectors

The increasing prevalence of chronic and life-threatening diseases has prompted pharmaceutical companies and research firms to focus on R&D activities for the development of effective therapeutics. As a result, advances in life sciences research is leading to an improved understanding of biological systems. The development of oligonucleotide synthesis technologies has helped pharmaceutical and biotechnology researchers with molecular-level development, design, and modification of biological systems. The increasing research activities in the pharmaceutical and biotechnology sectors will lead to the expansion of the global oligonucleotide synthesis market at a CAGR of over 10% during the forecast period.

Increasing focus on R&D of new oligonucleotide therapies

Pharmaceutical and biotechnological companies are focusing on R&D of new oligonucleotide drugs due to the presence of the limited number of approved drugs. Oligonucleotides efficiently target disease-relevant proteins and genes that are inaccessible by small-molecule drugs and biologic drugs. Recent advances have helped overcome challenges associated with the administration, cellular uptake, biodistribution, and side effects of oligonucleotide therapies. Currently, many oligonucleotide therapeutics are in various stages of clinical trials for the treatment of many diseases, including viral infections, rare genetic disorders, neural and neuromuscular conditions, and cancers. The presence of these drugs and increase in R&D is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global oligonucleotide synthesis market is moderately concentrated. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading oligonucleotide synthesis manufacturers, that include Agilent Technologies Inc., Danaher Corp., General Electric Co., GenScript Biotech Corp., Kaneka Corp., Merck KGaA, Nitto Denko Corp., QIAGEN NV, Sarepta Therapeutics Inc., and Thermo Fisher Scientific Inc.

Also, the oligonucleotide synthesis market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Agilent Technologies Inc.
  • Danaher Corp.
  • General Electric Co.
  • GenScript Biotech Corp.
  • Kaneka Corp.
  • Merck KGaA
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 04: MARKET SIZING
  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 06: MARKET SEGMENTATION BY END-USER
  • Market segmentation by end-user
  • Comparison by end-user
  • Pharmaceutical and biotechnology companies - Market size and forecast
  • 2018-2023
  • Research and academic institutes - Market size and forecast 2018-2023
  • Diagnostic laboratories - Market size and forecast 2018-2023
  • Hospitals - Market size and forecast 2018-2023
  • Market opportunity by end-user
PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE
  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity
PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 11: MARKET TRENDS
  • Increasing focus on R&D of new oligonucleotide therapeutics
  • Strategic collaborations and partnerships for oligonucleotide drug discovery
  • and development
  • Rise in demand for low-cost and high-throughput oligonucleotide synthesis
PART 12: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
  • Competitive scenario
PART 13: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Agilent Technologies Inc.
  • Danaher Corp.
  • General Electric Co.
  • GenScript Biotech Corp.
  • Kaneka Corp.
  • Merck KGaA
  • Nitto Denko Corp.
  • QIAGEN NV
  • Sarepta Therapeutics Inc.
  • Thermo Fisher Scientific Inc.
PART 14: APPENDIX
  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors
List of Exhibits
Exhibit 01: Product overview
Exhibit 02: Global healthcare market
Exhibit 03: Segments of global healthcare market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2018
Exhibit 18: End-user - Market share 2018-2023 (%)
Exhibit 19: Comparison by end-user
Exhibit 20: Pharmaceutical and biotechnology companies - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Pharmaceutical and biotechnology companies - Year-over-year growth 2019-2023 (%)
Exhibit 22: Research and academic institutes - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Research and academic institutes - Year-over-year growth 2019-2023 (%)
Exhibit 24: Diagnostic laboratories - Market size and forecast 2018-2023 ($ millions)
Exhibit 25: Diagnostic laboratories - Year-over-year growth 2019-2023 (%)
Exhibit 26: Hospitals - Market size and forecast 2018-2023 ($ millions)
Exhibit 27: Hospitals - Year-over-year growth 2019-2023 (%)
Exhibit 28: Market opportunity by end-user
Exhibit 29: Customer landscape
Exhibit 30: Market share by geography 2018-2023 (%)
Exhibit 31: Geographic comparison
Exhibit 32: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 33: North America - Year-over-year growth 2019-2023 (%)
Exhibit 34: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 36: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Impact of drivers and challenges
Exhibit 43: Vendor landscape
Exhibit 44: Landscape disruption
Exhibit 45: Vendors covered
Exhibit 46: Vendor classification
Exhibit 47: Market positioning of vendors
Exhibit 48: Agilent Technologies Inc. - Vendor overview
Exhibit 49: Agilent Technologies Inc. - Business segments
Exhibit 50: Agilent Technologies Inc. - Organizational developments
Exhibit 51: Agilent Technologies Inc. - Geographic focus
Exhibit 52: Agilent Technologies Inc. - Segment focus
Exhibit 53: Agilent Technologies Inc. - Key offerings
Exhibit 54: Danaher Corp. - Vendor overview
Exhibit 55: Danaher Corp. - Business segments
Exhibit 56: Danaher Corp. - Organizational developments
Exhibit 57: Danaher Corp. - Geographic focus
Exhibit 58: Danaher Corp. - Segment focus
Exhibit 59: Danaher Corp. - Key offerings
Exhibit 60: General Electric Co. - Vendor overview
Exhibit 61: General Electric Co. - Business segments
Exhibit 62: General Electric Co. - Organizational developments
Exhibit 63: General Electric Co. - Geographic focus
Exhibit 64: General Electric Co. - Segment focus
Exhibit 65: General Electric Co. - Key offerings
Exhibit 66: GenScript Biotech Corp. - Vendor overview
Exhibit 67: GenScript Biotech Corp. - Business segments
Exhibit 68: GenScript Biotech Corp. - Organizational developments
Exhibit 69: GenScript Biotech Corp. - Geographic focus
Exhibit 70: GenScript Biotech Corp. - Segment focus
Exhibit 71: GenScript Biotech Corp. - Key offerings
Exhibit 72: Kaneka Corp. - Vendor overview
Exhibit 73: Kaneka Corp. - Business segments
Exhibit 74: Kaneka Corp. - Organizational developments
Exhibit 75: Kaneka Corp. - Geographic focus
Exhibit 76: Kaneka Corp. - Segment focus
Exhibit 77: Kaneka Corp. - Key offerings
Exhibit 78: Merck KGaA - Vendor overview
Exhibit 79: Merck KGaA - Business segments
Exhibit 80: Merck KGaA - Organizational developments
Exhibit 81: Merck KGaA - Geographic focus
Exhibit 82: Merck KGaA - Segment focus
Exhibit 83: Merck KGaA - Key offerings
Exhibit 84: Nitto Denko Corp. - Vendor overview
Exhibit 85: Nitto Denko Corp. - Business segments
Exhibit 86: Nitto Denko Corp. - Organizational developments
Exhibit 87: Nitto Denko Corp. - Geographic focus
Exhibit 88: Nitto Denko Corp. - Segment focus
Exhibit 89: Nitto Denko Corp. - Key offerings
Exhibit 90: QIAGEN NV - Vendor overview
Exhibit 91: QIAGEN NV - Product segments
Exhibit 92: QIAGEN NV - Organizational developments
Exhibit 93: QIAGEN NV - Geographic focus
Exhibit 94: QIAGEN NV - Segment focus
Exhibit 95: QIAGEN NV - Key offerings
Exhibit 96: Sarepta Therapeutics Inc. - Vendor overview
Exhibit 97: Sarepta Therapeutics Inc. - Product segments
Exhibit 98: Sarepta Therapeutics Inc. - Organizational developments
Exhibit 99: Sarepta Therapeutics Inc. - Key offerings
Exhibit 100: Thermo Fisher Scientific Inc. - Vendor overview
Exhibit 101: Thermo Fisher Scientific Inc. - Business segments
Exhibit 102: Thermo Fisher Scientific Inc. - Organizational developments
Exhibit 103: Thermo Fisher Scientific Inc. - Geographic focus
Exhibit 104: Thermo Fisher Scientific Inc. - Segment focus
Exhibit 105: Thermo Fisher Scientific Inc. - Key offerings
Exhibit 106: Validation techniques employed for market sizing
Exhibit 107: Definition of market positioning of vendors
Note: Product cover images may vary from those shown
3 of 4
  • Agilent Technologies Inc.
  • Danaher Corp.
  • General Electric Co.
  • GenScript Biotech Corp.
  • Kaneka Corp.
  • Merck KGaA
  • Nitto Denko Corp.
  • QIAGEN NV
  • Sarepta Therapeutics Inc.
  • Thermo Fisher Scientific Inc.
Note: Product cover images may vary from those shown
4 of 4

Loading
LOADING...

Adroll
adroll